PASSReviewer 1· 85% conf
Methods are detailed, the trial is registered, limitations are thoroughly discussed, and funding/COI are disclosed; no reporting checklist is referenced.
Evidence
direct quote[Footnotes]
“Trial Registration: NCT05492955”direct quote[Discussion, paragraph 5]
“Our study is limited by its conduct in two clinics in one region of a single country.”absence[Methods; Footnotes]
No reporting guideline checklist is referenced.PASSReviewer 2· 90% conf
Most reporting transparency criteria are met; only a reporting guideline checklist is not referenced.
Evidence
direct quote[Footnotes]
“Trial Registration: NCT05492955”direct quote[Discussion, paragraph 5]
“Our study is limited by its conduct in two clinics in one region of a single country.”direct quote[Funding, Footnotes]
“This IMPACT-BP trial was funded by the US National Institutes of Health (R01 HL144848) and the Wellcome Trust (227167/A/23/Z).”PASSReviewer 3· 90% conf
The manuscript is well-reported with detailed methods, trial registration, outcome reporting, limitations, proportional conclusions, and funding/COI. The only gap is the lack of a reference to a specific reporting guideline (e.g., CONSORT).
Evidence
direct quote[Footnotes]
“Trial Registration: NCT05492955 (https://clinicaltrials.gov/show/NCT05492955) , registered August 5, 2022 SAHPRA Trial Number : N20211201 SANCTR Number: DOH-27-112022-4895”direct quote[Discussion, paragraph 5]
“Our study is limited by its conduct in two clinics in one region of a single country.”paraphrase[Funding and Footnotes]
“This IMPACT-BP trial was funded by the US National Institutes of Health (R01 HL144848) and the Wellcome Trust (227167/A/23/Z). ... Disclosure forms provided by the authors are available with the full text of this article at NEJM.org”